Anavex Life Sciences (AVXL) Price & Analysis

Compare

1,729 Followers

AVXL Stock Chart & Stats

$5.01

-$1.39(-10.33%)

At close: Jan 08 4:00 PM EST

$5.01

-$1.39(-10.33%)

Day’s Range― - ―

52-Week Range$2.86 - $13.99

Previous CloseN/A

Volume1.46M

Average Volume (3M)1.95M

Market Cap

$447.63M

Enterprise Value$661.88M

Total Cash (Recent Filing)$101.16M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.42

Next Earnings

Feb 05, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding89,348,110

10 Day Avg. Volume1,649,612

30 Day Avg. Volume1,946,254

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)8.00

Price to Sales (P/S)0.00

P/FCF Ratio-19.44

Enterprise Value/Market Cap1.48

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-11.47

Forecast

1Y Price Target

$20.00

Price Target Upside299.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.51

Revenue Forecast (FY)$221.71M

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyClinical trial results showing significantly less cognitive decline and clinically meaningful improvements in cognitive scores support blarcamesine's potential to delay Alzheimer's disease progression.

Regulatory Re-examinationEMA re-examination request would trigger a fresh review by different rapporteurs, offering a new assessment that could reverse the prior CHMP opinion on blarcamesine.

Safety And MechanismFavorable safety and tolerability, combined with sigma-1 receptor modulation and enhanced autophagy, strengthens the therapeutic rationale and may alleviate regulatory concerns.

Bears Say

Endpoint SensitivityQuestions about the sensitivity of the ADCS-ADL endpoint in early Alzheimer's patients weaken confidence that the trial demonstrates clear functional benefit.

Trial Data UncertaintyPhase 2b/3 and open-label extension data affected by trial disruptions create uncertainty about cohort adequacy and whether the dataset will meet approval standards.

Valuation And Market DependenceHeavy reliance of the stock's valuation on the EMA outcome and persistent bearish sentiment increase downside risk if regulators remain unconvinced.

Anavex Life Sciences News

Anavex joins ACCESS-AD, initiative for therapeutic approaches for Alzheimer’s

Anavex (AVXL) Life Sciences announced its participation as a key industry partner in ACCESS-AD, a European initiative designed...

7d ago

AVXL

Anavex appoints Wolfgang Liedtke as SVP, global head of neurologyRegeneron

Anavex Life Sciences (AVXL) announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head...

12d ago

AVXL

REGN

Anavex receives FDA feedback on Alzheimer’s disease program

Anavex (AVXL) Life Sciences announced that the U.S. Food and Drug Administration had invited the Company to present...

14d ago

AVXL

Anavex submits request for EMA to re-examine its opinion on blarcamesine

Anavex (AVXL) Life Sciences announced that it has requested the European Medicines Agency, EMA, to re-examine its opinion...

1M ago

AVXL

Promising Therapeutic Potential of Blarcamesine Sparks Buy Rating for Anavex Life Sciences

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences and keeping the price...

1M ago

AVXL

Anavex participates in a conference call with H.C. Wainwright

Healthcare Analyst Selvaraju holds a conference call with Prof. Dr. Marwan N. Sabbagh, Chairman of the Scientific Advisory...

1M ago

AVXL

Anavex announces negative CHMP opinion on blarcamesine MAA

Anavex (AVXL) provided an update on the regulatory review in the EU for blarcamesine to treat early Alzheimer’s...

1M ago

AVXL

Anavex Life Sciences: Strategic Positioning and Potential Reversal in Alzheimer’s Treatment Boost Buy Rating

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences and keeping the price...

2M ago

AVXL

Anavex Life Sciences: Navigating Legal Risks and Regulatory Challenges in a High-Stakes Industry

Anavex Life Sciences (AVXL) has disclosed a new risk, in the Litigation & Legal Liabilities category. Anavex Life...

2M ago

AVXL

Anavex Life Sciences Earnings Call: Mixed Sentiments and Future Prospects

Anavex Life Sciences (($AVXL)) has held its Q4 earnings call. Read on for the main highlights of the...

2M ago

AVXL

Anavex Life Sciences Reports Q4 2025 Financials and Updates

Anavex Life Sciences ( ($AVXL) ) has released its Q4 earnings. Here is a breakdown of the information...

2M ago

AVXL

Anavex reports Q4 EPS (11c), consensus (15c)

“There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million...

2M ago

AVXL

Anavex sees cash runway of over three years

Cash and cash equivalents of $102.6 million at September 30, 2025 compared to $132.2 million at September 30,...

2M ago

AVXL

Options Volatility and Implied Earnings Moves This Week, November 24 – November 26, 2025

This week, several major companies will be reporting earnings. Among them are Alibaba (BABA), Nio (NIO), Zoom Video...

2M ago

AVXL FAQ

What was Anavex Life Sciences’s price range in the past 12 months?

Anavex Life Sciences lowest stock price was $2.86 and its highest was $13.99 in the past 12 months.

What is Anavex Life Sciences’s market cap?

Anavex Life Sciences’s market cap is $447.63M.

When is Anavex Life Sciences’s upcoming earnings report date?

Anavex Life Sciences’s upcoming earnings report date is Feb 05, 2026 which is in 16 days.

How were Anavex Life Sciences’s earnings last quarter?

Anavex Life Sciences released its earnings results on Nov 25, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.04.

Is Anavex Life Sciences overvalued?

According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Anavex Life Sciences pay dividends?

Anavex Life Sciences does not currently pay dividends.

What is Anavex Life Sciences’s EPS estimate?

Anavex Life Sciences’s EPS estimate is -0.12.

How many shares outstanding does Anavex Life Sciences have?

Anavex Life Sciences has 89,348,110 shares outstanding.

What happened to Anavex Life Sciences’s price movement after its last earnings report?

Anavex Life Sciences reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 12.338%.

Which hedge fund is a major shareholder of Anavex Life Sciences?

Currently, no hedge funds are holding shares in AVXL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Anavex Life Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.11%

Trailing 12-Months

Asset Growth

-23.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences (AVXL) Earnings & Revenues

Historic Earnings Reports

AVXL Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mix of positive advancements in clinical trials and strong financial positioning, contrasted by the setback of a negative CHMP opinion in Europe for blarcamesine and a decrease in R&D spending. Despite the challenges, the company remains optimistic about its scientific data and future regulatory discussions.View all AVXL earnings summaries

AVXL Stock 12 Month Forecast

Average Price Target

$20.00

▲(299.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.56,4.8246153846153845,6.0892307692307694,7.353846153846154,8.618461538461538,9.883076923076924,11.147692307692308,12.412307692307694,13.676923076923078,14.941538461538462,16.206153846153846,17.470769230769232,18.735384615384614,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.56,4.8246153846153845,6.0892307692307694,7.353846153846154,8.618461538461538,9.883076923076924,11.147692307692308,12.412307692307694,13.676923076923078,14.941538461538462,16.206153846153846,17.470769230769232,18.735384615384614,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.56,4.8246153846153845,6.0892307692307694,7.353846153846154,8.618461538461538,9.883076923076924,11.147692307692308,12.412307692307694,13.676923076923078,14.941538461538462,16.206153846153846,17.470769230769232,18.735384615384614,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.33,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >